5% Lidocaine-medicated plaster for the treatment of chronic peripheral neuropathic pain: complex regional pain syndrome and other neuropathic conditions

Enrique Calderón, María Eloísa Calderón-Seoane, Rafael García-Hernández, Luis Miguel Torres, Enrique Calderón, María Eloísa Calderón-Seoane, Rafael García-Hernández, Luis Miguel Torres

Abstract

Objectives: Chronic neuropathic pain and chronic complex regional pain syndrome (CRPS), in particular, are debilitating and difficult-to-treat conditions that have a strong impact on patient's quality of life. The aim of this study was to evaluate the effectiveness of 5% lidocaine-medicated plaster as add-on therapy in patients with chronic peripheral neuropathic pain conditions, including CRPS.

Patients and methods: This was a single-center, prospective, observational study set in a specialized pain unit of a tertiary hospital in Spain. A total of 56 patients with long-standing peripheral neuropathic pain, ten of them with CRPS, received 5% lidocaine-medicated plaster as add-on analgesic therapy for 6 months.

Results: After 6 months of treatment, a ≥50% reduction in pain intensity was attained by 75% of patients, as measured by numeric rating scale (NRS) for pain. The average NRS score was reduced by 61% (4.7 points), from a baseline mean score of 7.8 to an end point mean score of 3.1. Marked improvements were also observed in the CRPS group: six out of ten patients achieved a ≥50% reduction in NRS score, and the average NRS score for patients with CRPS was reduced by 51% (4.0 points), from a baseline mean score of 7.9 to an end point mean score of 3.9. The improvements in pain intensity were partially translated into a decrease in disability index and in anxiety levels.

Conclusion: 5% Lidocaine-medicated plaster may be useful as add-on therapy for a number of peripheral neuropathic pain conditions, including CRPS.

Keywords: analgesic therapy; chronic pain; complex regional pain syndrome; peripheral neuropathic pain; topical lidocaine.

Figures

Figure 1
Figure 1
Change in average NRS over time by clinical entity. Abbreviations: CPSP, chronic postsurgery pain; CRPS, complex regional pain syndrome; DPN, diabetic polyneuropathy; NES, nerve entrapment syndrome; NRS, numeric rating scale; PHN, postherpetic neuropathy
Figure 2
Figure 2
The percentage of patients reporting at least 50% pain intensity reduction, as measured by NRS score, after 1 month, 3 months, and 6 months of treatment. Abbreviations: CPSP, chronic postsurgery pain; CRPS, complex regional pain syndrome; DPN, diabetic polyneuropathy; NES, nerve entrapment syndrome; NRS, numeric rating scale; PHN, postherpetic neuropathy.

References

    1. Jensen TS, Baron R, Haanpaa M, et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204–2205.
    1. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654–662.
    1. Mick G, Baron R, Finnerup NB, et al. What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manag. 2012;2(1):71–77.
    1. Bruehl S. Complex regional pain syndrome. BMJ. 2015;351:h2730.
    1. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173.
    1. O’Connell NE, Wand BM, McAuley J, Marston L, Moseley GL. Interventions for treating pain and disability in adults with complex regional pain syndrome. Cochrane Database Syst Rev. 2013;(4):CD009416.
    1. Casale R, Mattia C. Building a diagnostic algorithm on localized neuropathic pain (LNP) and targeted topical treatment: focus on 5% lidocaine-medicated plaster. Ther Clin Risk Manag. 2014;10:259–268.
    1. Mick G, Correa-Illanes G. Topical pain management with the 5% lidocaine medicated plaster – a review. Curr Med Res Opin. 2012;28(6):937–951.
    1. Versatis(R) [Ficha técnica] Aachen, Germany: Gruenethal Pharma; 2016.
    1. Frost SG. Treatment of complex regional pain syndrome type 1 in a pediatric patient using the lidocaine patch 5%: a case report. Curr Ther Res Clin Exp. 2003;64(8):626–629.
    1. Karmarkar A, Lieberman I. Management of complex regional pain syndrome type II using lidoderm 5% patches. Br J Anaesth. 2007;98(2):261–262.
    1. World Medical A World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194.
    1. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the neuropathic pain symptom inventory. Pain. 2004;108(3):248–257.
    1. Perez C, Galvez R, Huelbes S, et al. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes. 2007;5:66.
    1. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis. 1978;37(4):378–381.
    1. Fairbank JC, Couper J, Davies JB, O’Brien JP. The Oswestry low back pain disability questionnaire. Physiotherapy. 1980;66(8):271–273.
    1. Payares K, Lugo LH, Morales V, Londono A. Validation in Colombia of the Oswestry disability questionnaire in patients with low back pain. Spine (Phila Pa 1976) 2011;36(26):E1730–E1735.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370.
    1. Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry. 2003;25(4):277–283.
    1. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52(2):69–77.
    1. Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician. 2010;56(6):e202–e515.
    1. Allegri M, Baron R, Hans G, et al. A pharmacological treatment algorithm for localized neuropathic pain. Curr Med Res Opin. 2016;32(2):377–384.
    1. Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;(7):CD010958.
    1. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP) Arthritis Care Res (Hoboken) 2011;63(suppl 11):S240–S252.
    1. Moulin DE, Clark AJ, Gordon A, et al. Long-term outcome of the management of chronic neuropathic pain: a prospective observational study. J Pain. 2015;16(9):852–861.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅